Cleveland Clinic | Strategic Alliance Partners

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed populations that exhibit greater practice effects than others.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed why gaps remain in screening for patients with Parkinson disease who may be eligible for device-aided therapies.

The neurologist from Cleveland Clinic stressed the potential for responsive neurostimulation in older populations with epilepsy and the need for expanded research.

The director of the sleep disorders center at Cleveland Clinic discussed the data on lower sodium oxybate presented at AAN 2021.

The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the potential of a data-driven approach to classifying patients with MS.

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how novel dexterity measurements can improve prognostication of disease progression.

The Vice-Chair for Research at the Cleveland Clinic Neurological Institute discussed his team’s efforts to find the minimally effective dose of IMU-838.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his team’s investigations presented at the 2021 AAN Annual Meeting.

Findings on multiple cognitive end points and biomarkers support lecanemab’s therapeutic concept for the targeting of specific oligomeric species in the process of pathophysiological amyloid generation in Alzheimer disease.

The director of the Center for Neurological Restoration at Cleveland Clinic spoke to how identifying care gaps in Parkinson disease patients is not a niche issue, but part of a bigger problem.

The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the findings of his presentation at AAN 2021.

The neurologist from Cleveland Clinic discussed his study presented at AAN 2021 involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic spoke to a study using the digital Manual Dexterity Test.

The director of the sleep disorders center at Cleveland Clinic discussed her investigations into low-sodium oxybate presented at AAN 2021.

The Vice-Chair for Research at the Cleveland Clinic Neurological Institute discussed topline results from the EMPhASIS trial of IMU-838.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

The director of the Center for Neurological Restoration at Cleveland Clinic provided an inside perspective on how the MANAGE-PD tool can effectively assist in the Parkinson disease screening process.

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic, outlined the different tests that make up the MSPT battery.

The therapy has fewer off-target effects on kinases and may be better-tolerated than other DHODH inhibitors for patients with relapsing MS.

Researchers saw the least amount of adverse events and the least time to stable dose in participants entering the study with SXB treatment.

In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies.

Critically ill patients who were obtunded, stuporous, or comatose had pediatric lateralized epileptiform discharges, and acute brain insults were among many clinical characteristics to benefit from longer EEG.

Alise Carlson, MD, a resident at Cleveland Clinic, provided insight on how raising awareness for genetic leukodystrophies may ultimately improve misdiagnosis rates.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed whether lenalidomide, a repurposed cancer drug, has promise as an Alzheimer disease DMT.

Alise Carlson, MD, a resident at Cleveland Clinic, detailed the reasons for her study evaluating genetic leukodystrophies and their differences to multiple sclerosis at diagnosis.

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.

The findings suggest the externally altered proprioceptive feedback in forced exercises may be increasing cortical engagement.

Alise Carlson, MD, a resident at Cleveland Clinic, discussed her presentation from ACTRIMS Forum 2021 on the misdiagnosis of adult-onset genetic leukodystrophies as multiple sclerosis.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed the research opportunities for repurposed anti-inflammatory drugs for Alzheimer disease.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic provided an overview on how lenalidomide, an FDA-approved cancer drug, will be evaluated in Alzheimer disease.